Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright

Altimmune (NASDAQ:ALT) had its price target hoisted by HC Wainwright from $12.00 to $25.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts also recently weighed in on ALT. B. Riley Financial decreased their target price on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a report on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Barclays started coverage on Altimmune in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, Wall Street Zen downgraded Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.20.

Altimmune Stock Performance

Altimmune stock opened at $3.62 on Monday. The company has a 50 day moving average price of $4.49 and a 200-day moving average price of $4.30. The company has a market capitalization of $470.85 million, a PE ratio of -3.58 and a beta of 0.13. Altimmune has a fifty-two week low of $2.90 and a fifty-two week high of $7.73. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts forecast that Altimmune will post -1.35 earnings per share for the current year.

Insider Activity

In other news, Director John Gill acquired 12,500 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The shares were acquired at an average price of $4.10 per share, with a total value of $51,250.00. Following the purchase, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jerome Benedict Durso bought 20,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were purchased at an average cost of $3.54 per share, with a total value of $70,800.00. Following the completion of the acquisition, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. This represents a 160.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 55,527 shares of company stock worth $213,778. 4.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Altimmune by 13.4% in the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after buying an additional 228,995 shares in the last quarter. Brown Wealth Management LLC grew its stake in Altimmune by 131.0% in the 2nd quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock valued at $894,000 after acquiring an additional 131,059 shares during the period. Intech Investment Management LLC grew its stake in Altimmune by 102.9% in the 2nd quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock valued at $561,000 after acquiring an additional 73,482 shares during the period. Jefferies Financial Group Inc. increased its holdings in Altimmune by 40.0% in the 2nd quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock worth $135,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Altimmune by 43.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock worth $826,000 after acquiring an additional 64,175 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.